NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

The European clinical trial databases, which are maintained by the regulators, not the company, showed approval in October 2020. It takes a process of approval before then for it to show up then. Plus it was discussed by the company for 2 years previous and at that annual meeting just before in extensive detail.

But the endpoints on the DE/UK websites are NOT the same as what was presented at NYAS and the rest,

Besides which, it does not friggen matter that the endpoints were changed prior to unblinding. The key is they cannot be changed based on data from the trial. And everybody knows that plenty of data from the trial was available for years.

The rational they have provided for changing OS from the randomized design to ECA was that too many patients crossed to make the original OS analysis feasible. That is a prima facia case of changing the endpoints based on data from the trial.